Facilitate monitoring of KISQALI▼ with the Your Choice programme
The Your Choice programme can help facilitate monitoring of KISQALI patients in day-to-day practice:
- Monitor your patients in the COMFORT of their home
- CONFIDENCE in a service tailored to your needs
- Reduce COST through fewer hospital visits
Patients enrolled onto Your Choice with KISQALI will be assigned a dedicated nurse who will provide support to complement and enhance existing support from their NHS clinical team. Assistance is offered with monitoring.
This programme is offered for the first 6 months of treatment when support may be required the most, and it may be extended beyond on a case-by-case basis. In addition, the monitoring support will be provided at a location that is convenient for your patient, i.e. at home or work.
Benefits for you and your patients
For you: alleviates pressures during clinic by taking bloods and performing ECG assessments outside of hospital appointments
For your patients: reduces logistical challenges so patients may not have to come to clinic as often or for as long
KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1
ECG, electrocardiogram; HCP, healthcare professional.